期刊
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS
卷 56, 期 9-10, 页码 441-446出版社
WILEY-BLACKWELL
DOI: 10.1002/jlcr.3085
关键词
tritium; carbon-14; H-3; C-14; isotope; label selection; pharmaceutical research and development; tritiated water; metabolic stability; metabolic switching; radiolabel
Tritium (H-3) and carbon-14 (C-14) labels applied in pharmaceutical research and development each offer their own distinctive advantages and disadvantages coupled with benefits and risks. The advantages of H-3 have a higher specific activity, shorter half-life that allows more manageable waste remediation, lower material costs, and often more direct synthetic routes. The advantages of C-14 offer certain analytical benefits and less potential for label loss. Although H-3 labels offer several advantages, they might be overlooked as a viable option because of the concerns about its drawbacks. A main drawback often challenged is metabolic liability. These drawbacks, in some cases, might be overstated leading to underutilization of a perfectly viable option. As a consequence, label selection may automatically default to C-14, which is a more conservative approach. To challenge this C-14-by-default' approach, pharmaceutical agents with strategically selected H-3-labeling positions based on non-labeled metabolism data have been successfully implemented and evaluated for H-3 loss. From in-house results, the long term success of projects clearly would benefit from a thorough, objective, and balanced assessment regarding label selection (H-3 or C-14). This assessment should be based on available project information and scientific knowledge. Important considerations are project applicability (preclinical and clinical phases), synthetic feasibility, costs, and timelines.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据